MicroRNA-206: a Promising Theranostic Marker

Jan Novák1,2,3, Peter Kružliak1, Julie Bienertová-Vašků3,4, Ondřej Slabý4 and Miroslav Novák1

1. International Clinical Research Center, Department of Cardiovascular Diseases, St. Anne’s University Hospital Brno, Brno, Czech Republic
2. Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
3. Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
4. Molecular Oncology II, Central European Institute of Technology, Brno, Czech Republic

Corresponding author: Jan Novák, Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. Email: 324158@mail.muni.cz; Phone: +420 725 431 052

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2013.09.01; Accepted: 2013.10.14; Published: 2014.01.02

Abstract

MicroRNAs (miRs) are small non-coding RNAs that negatively regulate gene expression by binding to the 3′ untranslated regions (3′UTR) of their target mRNAs. MiRs were shown to play pivotal roles in tissue development and function and are also involved in the pathogenesis of various diseases including cancer.

MicroRNA-206, which belongs to the group of so-called “myomiRs”, is one of the most studied miRs thus far. In addition to being involved in skeletal muscle development and pathology, it has also been established that it is involved in the pathogenesis of numerous diseases including heart failure, chronic obstructive pulmonary disease, Alzheimer’s disease and various types of cancers.

The aim of this review is to provide a complex overview of microRNA-206, including regulating its expression, a brief description of its known functions in skeletal muscle and a complex overview of its roles in the biology and pathology of other tissues, emphasizing its significant diagnostic and therapeutic potential.

Key words: microRNA-206, Theranostic Marker

1. Introduction

MicroRNAs (miRNAs) are small non-coding RNAs, first discovered in the C. elegans nematode worm in 1993 [1]. According to the latest release of miRBase [2] 20 years later, there are now over 30,000 known mature miRNA sequences described in 206 species.

MiRNA Biogenesis (Figure 1) consists of several consecutive steps with the first one being transcribing the miRNA from its corresponding gene using RNA-polymerase II/III into the molecule called primary miRNA (pri-miR). In the nucleus, pri-miR is cleaved with Drosha/DGCR8 complex to form a precursor miRNA (pre-miR) that is transported from the nucleus with exportin-5 protein. In the cytoplasm, nuclease Dicer cleaves pre-miR, which leads to the generation of miRNA-miRNA* duplex. MiRNA* is usually degraded even though some miRNA* has been observed to function in a similar way to to miRNAs, i.e. they create a complex with Argonaute (Ago) proteins called (mi)RNA-induced silencing complex (RISC or miRISC). The miRNAs in this complex function as negative regulators of gene expression: they bind to the 3′-untranslated regions (3′-UTR) of their target mRNAs (in accordance with base complementarity) and this then leads either to target mRNA degradation or to translational inhibition [3].

One miRNA usually has more than one target mRNA and one mRNA is usually targeted by more than one miRNA [4], which leads to the formation of a huge regulatory network which plays a pivotal role in nu-
merous processes such as embryonic development, normal tissue functions and the pathogenesis of various diseases.

This review focuses on microRNA-206 (miR-206), a vertebrate specific miRNA, which is referred to as a skeletal muscle specific myomiR [5]. This miRNA shares the same seed sequence and at least some targets with miR-1 [2], which also belongs to the myomiR family along with miR-133a, miR-133b, miR-208a, miR-208b and miR-499 ([6], Figure 2); however miR-1 is expressed in both skeletal and cardiac muscles [7]. MiR-206 is being intensively studied in various contexts: skeletal muscle development [8, 9], function and pathology [5, 9], heart failure [10], various types of cancers [11-13] and other diseases [14-16]. The aim of this review is to introduce miR-206, provide a short description of its relevance in skeletal muscle biology as well as offering a more detailed description of this miRNA’s role in other conditions while placing special emphasis on its theranostic potential.

Figure 1: MicroRNA biogenesis pathway. MicroRNAs are transcribed from corresponding genes with RNA-polymerase II/III; the primary transcript is called primary-miRNA (pri-miR). Already in the nucleus, microprocessing complex Drosha/DGCR8 cleaves pri-miR to precursor miR (pre-miR) that is transported from the nucleus with Exportin 5. In the cytoplasm, the Dicer cleaves pre-miR: the passenger strand (miR*) is consecutively degraded and the mature strand (miR) is incorporated into the RNA-induced silencing complex (RISC). Within the RISC, base pairing between miR and target mRNA 3´untranslated region (3´UTR) occurs leading to target mRNA degradation or translational inhibition.

Figure 2: MyomiR family. The figure depicts the structure of a pre-miR-206 stem loop with the mature sequence indicated in a rectangle. Under the structure, there are sequences of all miRNAs from the human myomiR family with their seed sequences underlined. Next to the sequences, the miRNAs’ tissue specificity is visualized.
2. Regulation of microRNA-206 expression

The gene for human miR-206 (hsa-miR-206) is localized on chromosome 6 in a bicistronic cluster together with the gene for miR-133b [2]. The expression of these microRNAs can be regulated on different levels including chromatin remodeling, transcriptional and posttranscriptional regulation and is also under endocrinological and environmental control.

The chromatin remodeling enzyme, high mobility group box 1 protein (HMGB1), has previously been shown to increase miR-206 levels when injected into the chronically failing hearts of experimental animals [10]. In another cell type, the Th17-lymphocyte, it was reported that miR-206 and miR-133b are co-transcribed together with interleukin (IL)-17 when IL-23 is used [17]. This co-transcription is specific for T-lymphocytes (IL-17 is not detectable in skeletal muscle even after IL-23 stimulation) and may be affected both by chromatin remodeling, since the IL-17 gene is located near the genes for miR-206/133b, and transcription factors (TFs) specific for IL-17, e.g. STAT3 [17].

Various TFs important for skeletal muscle development have been shown to regulate miR-206 expression during skeletal muscle development; likewise, the proper spatiotemporal expression of these TFs is critical to successfully complete myogenesis [18]. One of the strongest inducers of myogenesis, and therefore also of mir-206, is Myf5 [19], which acts through MyoD [20-22] and myogenin [19] with MEF2C enhancement [23]. Negative regulation of miR-206 expression during myogenesis is carried out via myostatin, since myostatin knockout caused upregulation of all myomiRs in experimental animals [24]. Whether this regulation is direct or indirect still remains to be determined. The importance of proper myostatin-mediated negative myogenesis regulation was previously documented on Texel sheep where just one SNP in the 3’UTR of myostatin created a binding site for miR-1/206, resulting in these animals’ muscular phenotype [25]. Various autoregulatory loops which add robustness to this TF network have also been described, one of them involving Notch3 protein [23]. Notch3 expression is increased by MyoD at the beginning of muscle differentiation, thus ensuring MEF2C inhibition, which is important in the final stages of myogenesis. When cells are ready to finish the differentiation process, miR-1/206 targets Notch3, thereby inhibiting its function [23].

In addition to the above mentioned TFs, other molecules and various signal pathways have also been shown to increase or decrease miR-206 expression in various tissues (Figure 3). Song et al. [26] described a “dual inhibitory mechanism”, in which small heterodimer partner (SHP), a known nuclear transcriptional co-repressor, plays a role. In this model, SHP inhibits the expression of estrogen-related receptor γ (ERRγ) which is responsible for Ying Yang 1 (YY1) TF expression. A decrease in YY1 leads to the activation of TF activator protein 1 (AP1) and to an increase in miR-206 expression [26]. A study by Lu et al. [27] lists other significant players involved in this regulatory mechanism: NFkB, miR-29 and miR-1. NFkB stimulates and miR-1/29 inhibits YY1 signaling, thus inhibiting or activating miR-206 expression, respectively [27]. Other signals inhibiting miR-206 expression include e.g. Sonic Hedgehog (Shh) [28], fibroblast growth factors 2 and 4 (FGF2/FGF4) [29] signaling pathways and tumor growth factor β (TGFβ) [30].

---

Figure 3: Regulation of microRNA-206 expression.
The figure summarizes how miR-206 expression may be regulated or influenced. Red (blunt) arrows indicate inhibition/downregulation and green (sharp) arrows indicate activation/upregulation. Abbreviations are explained in the text.
The participation of thyroid hormones in the miR-206 regulation was described in mouse liver and corresponding cell line models [31] and in human skeletal muscle in patients with hypothyroidism [32]. Thyroid hormones and their substituents decrease miR-206 levels and hypothyroidism increases its expression [31, 32]; accordingly, miR-206 is also proposed to serve as an important mediator of thyroid hormone function since some of the miR-206 targets (e.g. Mup1 and Gpd2) were previously shown to be regulated by thyroid hormones [31]. Additional hormones to be considered in miR-206 regulation are estrogens, as shown in human breast cancer [33], where miR-206 further targets estrogen receptor α (ERα), i.e. one of the factors responsible for cancer cells’ ER-negative phenotype and an element affecting responsiveness to hormonal therapy [33].

Focusing on posttranscriptional regulation, bone morphogenetic protein 2 (BMP-2) was shown to inhibit pri-miR-206 to mature miR-206 processing [34]. BMP-2 has previously been shown to cause C2C12 myoblast cell lineage differentiation into osteoblasts when supplemented [35]; this was explained by its inhibition of MyoD and myogenin activity [36]. This study therefore further expands our understanding of the lineage switch process with BMP-2 inhibiting miR-206, myoD and myogenin activity, resulting in the inhibition of myogenic differentiation.

Last but not least, the effect of environmental factors on miR-206 expression needs to be mentioned. Essential aminoacids are known to be important for muscle growth and as such stimulate muscle protein synthesis – along with pri-miR-206 levels [37]. Physical exercise was repeatedly shown not to affect the circulating miR-206 levels [38, 39], which may become an advantage when monitoring the course of muscle dystrophies because circulating levels of currently used markers (e.g. creatinkinase) are affected [40, 41]. Endurance training did not significantly affect the levels of circulating miR-206 either; however, the basal expression of miR-206 in muscle tissue was significantly lower after 12 weeks and it returned to the pre-training values following 2 weeks of withdrawn training [42]. Interestingly, spaceflight has been shown to decrease miR-206 levels [43]. These results indicate that miR-206 is probably not involved in short-term muscle adaptation to physical exercise; however, everyday muscle activity is needed for its sustained expression and this basal expression may be reduced if these stimuli are either withdrawn (space-flight) or chronically increased (endurance training).

3. ROLES FOR MicroRNA-206 IN SKELETAL MUSCLE

3.1 Myogenesis and muscle regeneration (Figure 4)

Myogenesis is a complex process during which muscle progenitor cells leave the somites and migrate to final body locations where they proliferate and differentiate in order to create skeletal muscle [18]. MiR-206 is currently considered an important part of the myogenesis process in humans [44], mice [45], zebrafish [46], pigs [47, 48] and even common carp [49]. It can be specifically detected in the somites, with the highest expression in mouse embryos being detected 11.5-12.5 days post conception and tending to decrease from the 3rd day after birth [50]. If miR-206 and other miRNAs levels decrease due to Dicer knockout (this knockout results in global downregulation of most miRNAs), mice die prenatally [51]. If muscle-specific Dicer knockout is performed, it results in skeletal muscle hypoplasia and defective fiber morphology indicating the important role of microRNAs in muscle development [52].

Figure 4: Roles of microRNA-206 in muscle development and regeneration. MiR-206 involvement in muscle development with putative targets shown above black arrows. A comprehensive explanation may be found in the text.
The mouse myoblast cell line (C2C12) is the most commonly used cell line for the study of myogenesis. When C2C12 cells are cultured under high serum conditions, they remain in a proliferating state; however, if they are switched to low serum conditions, they begin to differentiate and fuse into myofibers [53]. The importance of miR-206 in myogenesis is highlighted by a study by Kim et al. [45]. This study indicated that even in stable serum conditions, adding miR-206 induces C2C12 cell differentiation and vice versa – if miR-206 is blocked and serum conditions are changed, no differentiation occurs [45].

Proper miR-206 downregulation and upregulation during different stages of myogenesis is crucial since it targets key molecules like paired box 3 (Pax3) and Pax7, both of which are important TFs for muscle progenitor cell migration and proliferation, respectively [18]. At the right moment, miR-206 needs to be upregulated (via the regulatory pathways described above and including Myf5, MyoD and others’) in order to initiate the muscle differentiation program. Inhibiting miR-206 expression using antagoniRs results in a delayed differentiation onset and improper migration of muscle progenitors [54]. Later, during myogenesis, miR-206 targets various genes enabling early and - subsequently - terminal differentiation [9], e.g. DNA-polymerase α (POL α) [45], histone deacetylase 4 (HDAC4) [30], utrophin [21] and connexin 43 (Cx43) genes [55]. Inhibiting POLα is important to terminate the proliferation program [45] at the beginning of differentiation, which is promoted by removing the inhibitory effects of HDAC4 on MEF2C [30]. The downregulation of utrophin seems to be important later in the myogenesis process [21] while follistatin [21] and Cx43 downregulation [55] play an important role in myocyte fusion into myofibers. This process naturally involves additional miRNAs, but a detailed description is clearly outside the scope of this review.

During myogenesis, part of the myoblasts enter quiescence, locate themselves between the basal membrane and sarcolemma [56] and remain in a self-renewing state which maintains their ability to enter the muscle differentiation program in the future if the muscle is injured [18]. In this case, miR-206 levels in SCs are downregulated, thus enabling Pax7 to increase while causing SCs proliferation [57]. After a short time, miR-206 levels return to the pre-injury state and SCs differentiate to replace the damaged rhabdomyocytes. When miR-206 is artificially added to injured skeletal muscle, it promotes muscle healing as shown in rat models in a study conducted by Nakasa et al. [58].

3.2 Innervation, reinnervation and amyotrophic lateral sclerosis (ALS)

In order to properly perform its function, skeletal muscle must be properly innervated; during innervation, skeletal muscle tissue cooperates with axons in order to create neuromuscular junctions (NMJ) (Figure 5). MiR-206 levels were found to be increased in NMJ [59], facilitating mutual communication between muscle fibers and motoneuron axons by targeting various molecules including brain-derived neurotropic factor (BDNF) and its receptor (p75NTR) [60], HDAC4 [59] and MEF2 [61].

Figure 5: MicroRNA-206 involvement in neuromuscular junctions function. The figure depicts neuromuscular junction (NMJ) with the neural cell marked in blue and muscle cell in red. During transmission (marked as yellow thunderbolts), myoD expression is enhanced, leading to the expression of miR-206, which further affects mutual communication between muscle and neural cell and affects reinnervation after denervation.
The experiments focused on reinnervation after a sciatic nerve injury showed that miR-206 expression remained unchanged immediately after denervation; however, it increased during the reinnervation process [61]. By targeting MEF2, miR-206 was proposed to affect muscle composition (fiber type) and to constitute one of the sources of the differences observed between healthy and reinnervated muscle [61]. However, these results were not confirmed by a subsequent study where miR-206 levels remained unchanged both after denervation and during reinnervation; the role of other myomiRs was thus emphasized [62].

Reinnervation has also been intensely studied in amyotrophic lateral sclerosis (ALS) [59, 63]. ALS is a neurodegenerative disease which causes a loss of motoneurons, resulting in the denervation of skeletal muscle, consequent paralysis and death [59, 63]. MiR-206 levels were shown to be upregulated in both mice [59] and humans [63]. In the mouse model, the effects of miR-206 were analyzed in detail using miR-206 knockdown animals. Although the ALS onset in these animals was the same as wild type animals, the progression of ALS was faster, resulting in a more severe phenotype, delayed reinnervation and subsequent over-innervation with motoric axons sprouting beyond the original NMJ area [59]. HDAC4, a miR-206 target was suggested to play a role in these effects and the entire signaling pathway, including miR-206/HDAC4/FGFBP1/FGF, was suggested as an explanation of these processes [59]. In human ALS samples, miR-206 was upregulated in both slow and rapid progression patients and only levels of HDAC4 served to distinguish between these groups, indicating that other signals are also necessary for the reinnervation process [63].

3.3 Muscular dystrophies

Muscular dystrophies (MD) represent a group of heritable diseases whose common sign is muscle weakness, often in a progressive form [64]. The most common X-linked and autosomal dominant MDs are Duchene MD and myotonic dystrophy type 1 (MDT1) respectively [64, 65]. The first study to report the dysregulation of myomiRs in Duchene MD was conducted by McCarthy et al. using mdx mice [66]. The study showed that miR-206 is downregulated in the plantaris muscle, but is increased in the diaphragm, most likely due to the upregulation of MyoD and possibly due to the functional denervation of the regenerating muscle [66]. Roberts et al. further confirmed that miR-206 levels also differ between muscle groups in an experimental animal [67]. It was also shown that miR-206 increase occurs during muscle regeneration [68, 69] and, since the diaphragm is the most affected muscle in mdx mice [66], high expression of miR-206 may indicate a high regenerative capacity of this muscle. Interestingly, Yuasa et al. reported that in CXMD dogs, which display a more severe phenotype than mdx mice, miR-206 levels are not increased, which may reflect insufficient regeneration [68]. All of the above mentioned information correlates with a subsequently reported observation, i.e. that miR-206 may be found mostly in satellite cells where it stimulates their differentiation in order to initiate muscle regeneration [70].

In MDT1, the miR-206 dysregulation and other muscle-specific miRNAs were described several years later [71, 72]. Whether miR-206 levels are upregulated [72] or unchanged [71] still remains to be elucidated by more extensive studies; however, in MDT1 patients, miR-206 is mislocalized within the cell compared to normal muscle tissue [71, 72].

The above mentioned studies clearly indicate that miR-206 is extensively involved in the pathophysiology of various muscle dystrophies. From a theranostic point of view, miR-206 levels (along with miR-1 and miR-133) were shown to be good serum biomarkers for DMD, correlating even with the severity of the disease [40, 67]. Since their levels are not affected by physical exercise [38-40] they may serve as more precise and valuable biomarkers than the currently used creatinkinase. Current studies also suggest that miR-206 may be used as a therapeutic tool in muscular dystrophy thanks to its reported pro-differentiating and disease-progression slowing effect [67, 73] (Figure 6).

4. MIR-206 IN TUMOR BIOLOGY (Figure 7)

4.1 Rhabdomyosarcoma

Rhabdomyosarcoma represents the most common soft tissue sarcoma with embryonal RMS (ERMS) being the most common type, followed by alveolar RMS (ARMS) [74]. Both of these tumors express markers specific to skeletal muscle; however, their cells are much less differentiated in comparison with muscle tissue [75]. Although the downregulation of miR-206 (and other myomiRs) has been observed repeatedly in both types, it is more prominent in ARMS, thus partially explaining its less differentiated phenotype and more aggressive clinical behavior [76-78].

Experiments reinducing miR-206 in RMS cell lines have led to decreased cell proliferation and migration properties and increased myogenic differentiation [76, 77]. Expression profiling in the RD18 ERMS cell line identified more than 700 mRNA levels to be affected by miR-206 transfection [77]. Cell line experiments were further extended by injecting
miR-206 directly into RMS mouse models which caused a significant decrease in tumor mass and an increase in the expression of differentiation markers implicating miR-206 as a RMS therapy [76, 77].

Clinical trials focusing on the association between miR-206 and RMS have also been conducted, resulting in circulating miR-206 being identified as a potent diagnostic marker: the levels of this microRNA are muscle-specific even if this microRNA is down-regulated in RMS tissue and its circulating levels are higher in RMS patients than in healthy controls [79]. MiR-206 also provides information about the prognosis of a patient: tumors expressing lower miR-206 levels are considered more aggressive with a poorer prognosis [80].

Figure 6: Roles of microRNA-206 in muscular dystrophies. The figure represents miR-206 involvement in muscular dystrophies (MD). The upper left circle emphasizes its role in MD pathophysiology, i.e. involvement in muscle regeneration and differentiation and being differentially expressed in distinct muscle groups. The upper right circle shows its possible use as a circulating biomarker of MD and its correlation with patient prognosis. The lower circle shows the potential to use miR-206 mimics in the treatment of MD.

Figure 7: MicroRNA-206 in tumors. The figure summarizes various cancer types where miR-206 levels and roles were investigated. The colors of the boxes on both sides correspond to the colors of the organs indicated in the human outline. The arrows indicate whether miR-206 levels are upregulated or downregulated.
4.2 Breast cancer

Breast cancer is the most common cancer in women [81]. In most cases, ERα is present and provides an enormous theranostic potential: its presence facilitates both disease classification and the tailoring of individual therapy. MicroRNA array analysis identified microRNA deregulations in this cancer [82] with miR-206 being increased in ERα negative and decreased in ERα positive breast cancer [83, 84]. ERα was repeatedly shown to be a target for miR-206 [33, 83, 85, 86] and two miR-206 binding sites were found to be localized in its 3’UTR, along with binding sites for a number of additional miRNAs [33]. Moreover, miR-206 also targets steroid receptor coactivators (SRC)-1 and SRC-3 and TF GATA-3, all of which are part of estrogen-mediated signaling pathways; miR-206-mediated inhibition thus disrupts estrogen signaling on more levels than simply affecting ERα expression [87].

MiR-206 levels and activity in breast cancer are subject to the influence of numerous factors. Estradiol activation of ERα causes miR-206 downregulation [33]; however, this regulatory circuitry may be distracted by epidermal growth factor (EGF) signaling (applying both estradiol and EGF does not decrease miR-206 partly through the EGF-receptor/MAPK pathway [87]. On the contrary, miR-206 activity may be increased when ellagic acid is used [88] or when a single nucleotide polymorphism (rs9341070) in ERα 3’UTR is present – as it increases miR-206 binding [33], or when Ago2 protein levels are increased – as observed in breast cancer cells [89]. The factors contributing to increased miR-206 activity also contribute to ERα negativity [89] and consequently to a poorer prognosis.

Thus far, applying miR-206 to breast cancer cell lines has been shown to decrease cell growth [83, 85] due to cell cycle arrest [11, 83, 86] and to decrease cell proliferation following estradiol stimulation [86]. Underlying cell growth decrease mechanisms include the cyclinD2 downregulation, an important molecule inducing cell cycle entry [11] and hepatocyte growth factor receptor (MET) downregulation [85]. These results indicate miR-206’s future therapeutic potential in breast cancer therapy.

MiR-206 has also been identified as a metastasis-preventing microRNA [90] and its decreased levels have been associated with advanced clinical stages and the presence of lymph node metastasis [91]. Even if its levels do not correlate with prognostic parameters, pre-miR-206 SNP (rs6920648) presence affects patient survival (HR 0.77, p = 0.02), with stronger associations being observed in Caucasians and women with ER+ tumors than in African Americans [92]. However, how exactly this SNP affects miR-206 biogenesis still remains to be clarified.

4.3 Other cancers

As miR-206’s potential roles in other cancers are currently being intensely studied, only a limited number of studies are currently available (Table 1). Some of these studies focus on the microRNA profiling of specific cancers [93-95], others evaluate the potential link of miR-206 expression levels to the clinical outcomes of individual patients [96, 97] and still others evaluate the miR-206’s potential use in treatment [12, 98].

| Cancer                  | Significance of miR-206                                                                 | Ref. |
|------------------------|----------------------------------------------------------------------------------------|------|
| Endometrial carcinoma  | In ERα+ endometrial endometroid carcinoma, miR-206 levels are decreased and correlate negatively with ERα levels. Introduction of miR-206 causes cell cycle arrest and affects invasiveness. Lower expression of miR-206 indicates worse prognosis. Prognostic signature of miR-206 and additional four miRs (let-7a, miR-21, miR-135a, miR-335) may be used to detect metastases. Downregulation of miR-206 dysregulates miR-206/KLF4 feedback loop which is involved in cancer development. | [101] |
| Colorectal carcinoma   |                                                                                       | [96] |
| Gastric cancer         | Low expression of miR-206 indicates presence of metastases, venous invasion and higher probability of hematogenous recurrence along with shortened overall survival. MiR-206 targeting of cyclinD2 is partially responsible for decrease in cell growth and impaired colony growth of gastric cancer cell lines. | [12, 97] |
| Lung cancer            | Low expression of miR-206 was detected in samples with metastasis. Transfection of miR-206 caused decrease in cell proliferation, migration and invasion and induced apoptosis. Lung carcinoma 4-(methylnitrosamino)-1-(3-pyridyl)-1-butane increases levels of miR-206 (and miR-133b) in plasma of exposed rats. | [13] |
| Osteosarcoma           | MiR-206 is one of the downregulated microRNAs in osteosarcoma.                          | [105] |
| Naso-pharyngeal cancer | MiR-206 is one of 13 identified microRNAs suggested to play important roles in nasopharyngeal cancer. | [106] |

Table 1: Overview of miR-206 roles in other cancers

http://www.thno.org
carcinoma development.
Levels of miR-206 increased when lymph node metastasis were present. 
[99]
Laryngeal cancer
Levels of miR-206 are downregulated in laryngeal carcinoma patients.
Induction of miR-206 in cancer cell lines causes decrease in viability and invasive potential and increase in apoptosis.
Application of miR-206 into mouse model leads to significant decrease in tumor mass. 
[93, 96, 97]
Ovarian cancer
MiR-206 is higher in CD133+ cells (ovarian cancer stem cells) compared to CD133- cells. 
[107]
Prostate cancer
MiR-206 expression does not change during the progression of prostate cancer from intraepithelial neoplasia to metastases. 
[112]
Renal cell carcinoma
MiR-206 is downregulated in clear cell renal cell carcinoma and inhibits cancer cell proliferation. 
[94, 108]
Prolactinoma
Bromocriptine treatment increases levels of miR-206 in prolactinomas which may partly explain bromocriptine-induced apoptosis. 
[98]
Vestibular schwannoma
MiR-206 is significantly downregulated in schwannoma cells. 
[95]
Glioma and neuroblastoma
MiR-206 is downregulated in tumor cell lines and its transfection leads to apoptosis, in part by targeting Otx2. 
[109]
Waldenström macro-globulinemia
MiR-206 levels are upregulated in Waldenström macroglobulinemia cells accounting for modulation of histone deacetylation in part by targeting HAT (Mycot3) protein. 
[110]

The studies reviewed in Table 1 clearly indicate that the downregulation of miR-206 is associated with poorer patient prognosis, most notably due to the increased metastatic potential of the listed cancers [13, 96, 97]. A potential explanation for this phenomenon may be found in the miR-206 targeting of VEGFA, an important angiogenesis factor, as shown in laryngeal cancer [99] or during zebrafish development [100]. In the latter study, miR-1/206 knockdown zebrafish exhibited larger intersegmental vessel diameter and an increased number of endothelial cells [100]. While this finding needs to be further confirmed on different tumors and in larger cohorts, it may be hypothesized that miR-206 downregulation is a general sign of tumorigenicity which enables neoangiogenesis and the proliferation of tumor cells.

5. ROLES FOR MIR-206 IN OTHER TISSUES AND DISEASES

5.1 Myocardial infarction, heart failure and dilated cardiomyopathy

Various studies indicate that in spite of the muscle-specific character of miR-206, it may also play a pivotal role in the heart muscle [10, 111, 112] and associated conditions. The first study connecting miR-206 to the heart was conducted by Shan et al. [112] and showed that in a mouse model of myocardial infarction, levels of miR-1 and miR-206 are increased in infarcted tissue [112]. The authors suggest that both selected miRs may be involved in apoptotic signaling via IGF-1, leading to cardiomyocyte dysfunction [112]. The same group also showed that myocardial injury is further promoted by miR-206 targeting heat-shock protein 60 (Hsp60) in in vitro and in vivo models of diabetes. An increase in miR-1 and miR-206 was probably induced by a MEK1/2 increase which caused a serum response factor (SRF) increase which induced the expression of the above mentioned miRNAs by binding to specific response elements (RE 2,3,4 for miR-1 and RE5 for miR-206) [111]. A miR-206 increase was also observed in a rat model of heart failure and was even more prominent in mice treated with HMGB1 [10]. Administering HMGB1 improved cardiac function along with collagenolytic activity and decreased cardiac remodeling in experimental animals. These effects may be at least in part explained by an miR-206-induced decrease in tissue inhibitor of metalloproteinase 3 (TIMP-3) levels, thus enabling an increase in matrix metalloproteinase (MMP)2 and MMP9 [10].

Last but not least, miR-206 is involved in E2F6-induced dilated cardiomyopathy (DCM) [113]. E2F6 represses the E2F/Rb signaling pathway; transgenic mice in which E2F6 expression was sustained until adulthood generally present with DCM leading to heart failure. E2F6 dysregulation in Tg mice was associated with ERK pathway activation leading to an increase in miR-206 levels and Cx43 downregulation leading to DCM and electrical instability [113] (Figure 8).

5.2 Pulmonary hypertension, COPD and infectious respiratory diseases

It has been suggested previously that the development of pulmonary artery hypertension (PAH) resembles tumor growth to a certain degree, especially due to the devastating proliferation of smooth muscle cells (SMC) [114]. As in the case of tumors, mouse models of pulmonary hypertension have likewise shown downregulated miR-206 levels in examined tissue [14, 115] and upregulated in serum [14]. However, other recently conducted studies present contradictory results. Jalali et al. showed that transfecting miR-206 to pulmonary artery SMCs (PASMCs) caused a decrease in proliferation and cellular migration and an increase in apoptosis, probably due to a decrease in Notch3 signaling. Notch3 is a
known repressor of SMC differentiation and miR-206-mediated inhibition results in an increase of SMC differentiation markers, such as calponin and SM specific α-actin. Notch3 is also known to be involved in the pathogenesis of PAH and its inhibition by miR-206 may serve as a potential treatment for PAH in the future [115]. Contradictory results, namely a miR-206-mediated increase in proliferation, has been observed in a study by Yue et al.; miR-206 was shown to target HIF-1a, thus affecting the HIF-1a/Fhl-1 pathway; however, miR-206 transfection paradoxically led to an increase in HIF-1a levels [14]. Future studies are therefore needed to shed more light on the role of miR-206 in PAH pathogenesis.

Furthermore, it is known that PAH often develops as a result of COPD [116]. Increased levels of miR-206 and other muscle-specific miRs were established in COPD patients sera samples; these levels negatively correlated with the function of the quadriceps muscle [16] in which miRNA expression analysis previously showed altered miRNA expression [117]. An increase in serum levels of miR-206 is probably the result of increased muscle turnover, fiber type shift and muscle wasting in COPD patients; circulating miR levels may thus serve as biochemical markers of muscle performance [16].

MicroRNAs have also been shown to play a role in infectious respiratory diseases as they participate in agent-host interactions [118]. Using porcine models, miRNA expression profiles were found to be changed and miR-206 levels being upregulated in both porcine reproductive and respiratory syndrome virus (PRRSV) [118] and influenza virus [119] infections. Targeting viral RNAs and miRNAs of various inflammatory molecules (determined using computational prediction) indicates potential roles for miR-206 in antiviral response [118, 119].

In humans, miR-206 serum levels have been proven to be differentially expressed in pertussis patients in comparison with healthy controls [120]. Using a panel of five microRNAs (miR-202, miR-342-5p, miR-206, miR-487b, miR-576-5p), the authors were able to diagnose pertussis with a sensitivity of 97.4 % and a specificity of 94.3 % (cut off 0.707) [120].

5.3 Central nervous system

The brain is the most complex organ in the human body. Various miRNAs were shown to be upregulated or downregulated in distinct parts of the brain, which therefore supports their possible area-specific functions: e.g., miR-206 is detected at higher levels in the cerebellum than in the amygdala, the hippocampus or substantia nigra of adult male rats [121]. In a healthy brain, however, miR-206 can be detected only at very low levels, which may be important for proper neural system development: introducing miR-206 into the oligodendrocyte cell line CG-4 causes a decrease in tubulin polymerization-promoting protein (TPPP)/p25, which results in inhibiting oligodendrocyte differentiation [122].

Figure 8: Roles for microRNA-206 in cardiac diseases. In a healthy heart, miR-206 levels are barely detectable. In diseased conditions, its levels increase, leading to the apoptosis of the cells after myocardial infarction or in some cases, diabetic cardiomyopathy. In E2F6-induced dilated cardiomyopathy cases, increased miR-206 levels lead to electrical instability. However, heart failure cases, miR-206 overexpression seems to improve cardiac function and positively affect cardiac remodeling.
An increase in miR-206 levels has been observed in various pathological conditions and has been shown to be of theranostic significance [123-125]. During ischemia/reperfusion injury of the brain [123], miR-206 levels correlate with infarct size in a rat embolic stroke model, i.e., its levels increase during the first two days, followed by a continuous decrease [15]. Similar correlations were observed in mRNA levels of genes controlled by miR-206 (BDNF, Notch3, Cx43 and Otx2) [15]. MiR-206 levels are also upregulated in Alzheimer’s disease; downregulation reached by the delivery of antagomiRs (either directly intraventricularly or indirectly intranasally) caused a prominent increase in memory function, synaptogenesis and neurogenesis in the hippocampus [124]. This may serve as a promising strategy for future Alzheimer’s disease management. Last but not least, with respect to schizophrenia, miR-206 SNPs (rs17578796 and rs1700) were associated with the occurrence of this disease [125]. MiR-206 was shown to target genes previously associated with schizophrenia [125, 126] while also targeting the RNAs of several viruses (e.g., coxsackievirus B2, poliovirus 1) which were shown to affect neural cell function [126].

5.4 Other roles of microRNA-206

MicroRNA-206 has already been found to be involved in posttranscriptional regulation of numerous processes throughout the body and seems to be potentially useful in clinical practice. Other organs, diseases and conditions where miR-206 was shown to play a role are summarized in Table 2 and it may be expected that more roles for miR-206 will be provided in the near future.

### Table 2: Roles of miR-206 in other diseases

| Tissue                     | MiR-206 significance                                                                 | Ref |
|---------------------------|--------------------------------------------------------------------------------------|-----|
| Scleroderma               | MiR-206 along with miR-21 may serve as a potential diagnostic tool for scleroderma. | [127]|
| Pain control              | MiR-206 inhibits the expression of substance P from its mRNA in human mesenchymal-stem-cells-derived neuronal cells. | [128]|
|                           | MiR-206 levels are changed in dorsal root ganglion and spinal cord dorsal horn in CFA-induced inflammatory response or during sciatic nerve ligation. | [129]|
| Biorhythms                | MiR-206 is a part of the MyoD-miR-206-CLOCK-MyoD regulatory loop and thus participates in circadian rhythms regulation. | [130]|
| Brown adipose tissue      | MiR-206 expression is abundant in brown adipocytes and is missing in white adipocytes. This supports the idea that brown adipocytes and myocytes originate from a common cell lineage. | [131]|
| Liver steatosis           | MiR-206 suppresses liver X receptor α (LXRα) levels, thus inhibiting lipogenesis and serving as a potential therapeutic tool for future treatment of lipogenesis-associated diseases such as liver steatosis. | [132]|

### 6. Conclusions

Under physiological conditions, miR-206 may be skeletal-muscle-specific [5, 7]; however, under pathological conditions, its pleiotropic character is shown to be involved in the pathogenesis of various diseases, including heart failure [10], different types of tumors such as rhabdomyosarcoma [22, 76, 77] and breast cancer [11, 33, 83, 91] or neurological disorders such as Alzheimer’s disease [124]. In most of the above mentioned diseases, miR-206 levels are downregulated, which leads to the recognition of this miRNA as “disease-preventing”. In muscle dystrophies, where miR-206 is upregulated, this upregulation seems to be of “self-treating” significance [66, 73]. Alzheimer’s disease is an exception from this "disease-preventing rule", since in this case miR-206 upregulation does more harm than good by decreasing levels of BDNF, a molecule involved in neuronal plasticity and other brain functions [124].

MiR-206’s importance is further highlighted by the many factors known to be involved in its regulation. The complex network of regulatory mechanisms results not only in miR-206’s tissue-specific expression [7] but also in area- or locality-specific expression as shown in various types of muscle [66, 67] and distinct parts of the brain [121]. Whether these slight differences affect the precise functions of the above mentioned tissues (e.g., by affecting fiber type or neurotransmission), must be determined by future studies.

Using many examples, miR-206 was shown to have great theranostic potential for future clinical practice, serving as a disease biomarker, a disease progression and patient prognosis marker and in some cases even serving as a treatment tool. To diagnose a disease, more than one miRNA is generally necessary and more miRNAs create a specific pattern which facilitates the ability to distinguish different diseases. While MiR-206 is very often part of these patterns, its elevated circulating levels on their own may also be enough to identify patients with rhabdomyosarcoma [79] or to assess the severity of muscle wasting in patients with COPD [16].

With respect to the therapeutic potential of miR-206, both currently suggested methods using miR mimics and antagomiRs may be used [133]. Us-
ing miR-206 mimics should lead to its level restoration in diseased tissue and the restoration of many target protein levels and thus to an improvement of the disease or its cure. This has already been suggested for rhabdomyosarcoma [76, 77], muscle dystrophies [73] and pulmonary hypertension [134]. AntagomiR against miR-206 may – on the other hand – offer a promising strategy to deal with Alzheimer’s disease [124].

Using miRNAs as treatment tools is currently becoming a reality since there are biotech companies focusing on the use of miRNAs in diagnostics as well as pharmaceutical companies finalizing preclinical research phases and proceeding to clinical trials. In the case of liver cancer, one of the miRNAs, miR-34a, has already entered Phase 1 (NCT01829971). In the case of miR-206, MiRagen therapeutics is now in the “lead optimization” phase of research for using this miRNA as treatment for neuromuscular disorders [131].

In conclusion, miRNAs, and especially miR-206, have great theranostic potential; its real significance will most likely be determined in the very near future.

Abbreviations

miRNA/miR: microRNA; mRNA: messenger RNA; DGCR8: DiGeorge syndrome critical region 8; UTR: untranslated region; Ago: Argonaut; hsa: homo sapiens; HMGBl: high mobility group box 1 protein; IL: interleukin; TF: transcription factor; MyoD: myocyte differentiation; MFEC2: myocyte enhancer factor 2C; SHP: small heterodimer partner; ERRγ: estrogen-related receptor γ; YY1: Ying Yang 1; API: activator protein 1; NFXb: nuclear factor κ B; Shh: Sonic Hedgehog; TGFβ: tumor growth factor β; FGF: fibroblast growth factor; FGF4: fibroblast growth factor 4; ERα: estrogen receptor α; BMP-2: bone morphogenetic protein 2; Pax3: paired box 3; Pax7: paired box 7; POLα: DNA-polymerase α; HDAC4: histone deacetylase 4; Cx43: connexin 43; SCs: satellite cells; NMJ: neuromuscular junction; BDNF: brain-derived neurotrophic factor; ALS: amyotrophic lateral sclerosis; FGFBP1: fibroblast growth factor binding protein 1; FGF: fibroblast growth factor; MD: muscular dystrophy; mdx: muscular dystrophy; DMD: Duchenne muscular dystrophy; MDT1: myotonic dystrophy type 1; CXMD: canine X-linked muscular dystrophy; RMS: rhabdomyosarcoma; ERMS: embryonal rhabdomyosarcoma; ARMS: alveolar rhabdomyosarcoma; SRC1: steroid receptor coactivator 1; SRC3: steroid receptor coactivator 3; EGF: epidermal growth factor; MAPK: mitogen activated protein kinase; MET: hepatocyte growth factor receptor; SNP: single nucleotide polymorphism; VEGF: vascular endothelial growth factor; KLF4: Krüppel Like-Factor 4; CD: cluster of differentiation; Hsp: heat-shock protein; RE: response elements; TIMP-3: tissue inhibitor of metalloproteinase 3; MMP: matrix metalloproteinase; DCM: dilated cardiomyopathy; PAH: pulmonary artery hypertension; SMC: smooth muscle cells; PASMC: pulmonary artery SMC; HIF: hypoxia-inducible factor; COPD: chronic obstructive pulmonary disease; PRRSV: porcine reproductive and respiratory syndrome virus; TPPP: tubulin polymerization-promoting protein; LRXα: liver X receptor α

Acknowledgement

This work was supported by the European Regional Development Fund – Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123) and by the MUNI/A/0951/2012 grant. We would like to gratefully thank Mr. Matthew Smith for careful proof-reading of the manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1995; 79: 843-54.
2. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic acids research. 2011; 39: D152-7. doi:10.1093/nar/gkq1027.
3. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: a review. Journal of physiology and biochemistry. 2011; 67: 129-39. doi:10.1007/s13105-010-0050-6.
4. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433: 769-73. doi:10.1038/nature03135.
5. McCarthy JJ. MicroRNA-206: the skeletal muscle-specific myomiR. Biochimica et biophysica acta. 2008; 1779: 682-91. doi:10.1016/j.bbabio.2008.03.001.
6. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, et al. A family of microRNAs encoded by myosin governs myosin expression and muscle performance. Developmental cell. 2009; 17: 662-73. doi:10.1016/j.devcel.2009.10.013.
7. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Current biology : CB. 2002; 12: 735-9.
8. Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. The international journal of biochemistry & cell biology. 2010; 42: 1252-6. doi:10.1016/j.biocel.2009.03.002.
9. Novak J, Vinklarek J, Bienertova-Vasku J, Slaby O. MicroRNAs involved in skeletal muscle development and their roles in rhabdomyosarcoma pathogenesis. Pediatric blood & cancer. 2013. doi:10.1002/hlc.24664.
10. Limana F, Espósito G, D’Arcangelo D, Di Carlo A, Romani S, Mellito G, et al. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PloS one. 2011; 6:e19845. doi:10.1371/journal.pone.0019845.
11. Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, et al. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochemical and biophysical research communications. 2013; 433: 207-12. doi:10.1016/j.bbrc.2013.02.084.
12. Zhang L, Liu X, Jin H, Cao X, Xia L, Chen Z, et al. miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett. 2013; 332: 94-101. doi:10.1016/j.canlet.2013.01.023.
13. Wang X, Ling C, Bai Y, Zhao J. MicroRNA-206 is associated with invasion and metastasis of lung cancer. Journal of thoracic oncology. 2007; 2: 88-92. doi:10.1016/j.jto.2006.12.027.
14. Yue J, Guan J, Wang X, Zhang L, Yang Z, Ao Q, et al. MicroRNA-206 is involved in hypoxia-induced pulmonary hypertension through targeting of the HIF-1alpha/Fhl-1 pathway. Lab Invest. 2013; 93: 748-59. doi:10.1038/lab.2013.63.

http://www.thno.org
Theranostics 66. morphogenetic protein Sato MM, Nashimoto M, Katagiri T, Yawaka Y, Tamura M. Bone Molecular endocrinology (Baltimore, Md). 2007; 21: 1132 -47. ERalpha messenger RNA and protein expression in breast cancer cell lines. ribonucleic acid (miRNA) -0782. muscle transcripts. The Journal of clinical endocrinology and metabolism. J, et al. Physiological thyroid hormone levels regulate numerous skeletal cells by suppressing the transcriptional activity of MyoD and myogenin. - Experimental cell research. 1997; 230: 342 -71. doi:10.1016/s0009-8364(00)00275-3. Sweetman D, Goljane k K, Rathjen T, Oustanina S, Braun T, Dalmay T, et al. Specific requirements of MRs for the expression of muscle specific miRNAs and miR-206 and miR-133. Developmental biology. 2008; 321: 491-9. doi:10.1016/j.ydbio.2008.06.019. Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y, Asakura A. MyoD regulates apoptosis of myoblasts through miRNA-mediated downregulation of myostatin. The Journal of cell biology. 2010; 191: 147-63. doi:10.1010/jcb.201006025. Rosenberg MG, Kolesik S, Asawachaicharm A, Analau E, Tappolet SJ, MyoD. miRNAs and Ut rm expression by induction transforming miR-206. The Journal of cell biology. 2006; 175: 77-85. doi:10.1083/jcb.200603039. Mestrel J, Cerdà Z, Young JM, Calvo J, Tappolet SJ. miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells. Skelet Muscle. 2012; 2: 7. doi:10.1186/2044-5002-2-7. Cao Y, Dev BR, Yang R, Yuan D, Datta A. Notch3 and Mef2c proteins are growth to differentiation in rhabdomyosarcoma cells. Skelet Muscle. 2012; 2: 7. doi:10.1186/2044-5002-2-7. Gagan J, De BK, Layer R, Yan Z, Dutta A, Dutta A. Muscle specific microRNA miR-206 promotes muscle differentiation. The Journal of cell biology. 2006; 174: 677-87. doi:10.1083/jcb.200603008. Shkumatava A, Sla gian R, Bartel DP. Somatic but not overlapping regulation of microRNAs and their targets during vertebrate development. Genes & development. 2009; 23: 466-81. doi:10.1101/gad.174709. Hou X, Tang Z, Liu H, Wang N, Hu J, Li K. Discovery of MicroRNAs associated with myocarditis by deep sequencing of serial developmental skeletal muscles in pigs. PloS one. 2012; 7: e52123. doi:10.1371/journal.pone.0035212. Xie XS, Huang TH, Shen Y, Li XY, Zhang XX, Zhu MJ, et al. Identification and characterization of microRNA miR-133b that regulates myocardial sarcomere muscle animal. Genetics. 2010; 179: 919-936. doi:10.1093/molgenism/mol091.x. Yan X, Ding L, Li Y, Zhang X, Liang Y, Sun X, et al. Identification and profiling of microRNAs from skeletal muscle of the common carp. PloS one. 2012; 7: e30925. doi:10.1371/journal.pone.0030925. Takada S, Berezovik E, Yasamitha Y, Lagos-Qintana M, Kosterman WP, Emontom M, et al. Mouse microRNA profiles determined with a new and sensitive cloning method. Nucleic acids research. 2006; 34: e115. doi:10.1093/nar/gkj653. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, et al. Dicer is essential for mouse development. Nature genetics. 2003; 35: 215-7. doi:10.1038/ng.1253. O’Rourke JR, Georges SA, Seay HB, Tappolet SJ, McManus MT, Goldhamer DJ, et al. Essential role for Dicer during skeletal muscle development. Developmental biology. 2007; 313: 359-68. doi:10.1016/j.ydbio.2007.08.032. Nakajima N, Takashiki T, Kitamura R, Isodono K, Asada S, Ueyama T, et al. MicroRNA-1 facilitates skeletal myogenic differentiation through osteoblast and adipogenic differentiation. Biochemical and biophysical research communications. 2006; 350: 1006-12. doi:10.1016/j.bbrc.2006.09.153. Goljane k-Whyssl K, Sweetman D, Abu-Elmagd M, Chapnik E, Dalmay T, Hornstein E, et al. MicroRNA regulation of the paired-box transcription factor Pax3 confers robustness to developmental timing of myogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108: 11936-41. doi:10.1073/pnas.1103562108. Anderson C, Catoe H, Werner R. miR-206 regulates connexin43 expression during skeletal muscle development. Nucleic acids research. 2006; 34: 5863-71. doi:10.1093/gk/jlt043. Cerletti M, Shadrach JL, Jurj S, Sherwood R, Wagers AJ. Regulation and function of skeletal muscle stem cells. Cold Spring Harbor symposia on quantitative biology. 2008; 73: 317-22. doi:10.1101/cshperspect.a007304. Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, et al. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. The Journal of cell biology. 2010; 190: 867-79. doi:10.1083/jcb.200910156. Nakasa T, Ishikawa M, Shi M, Shibuya H, Adachi N, Ochi M. Acceleration of skeletal muscle injury model. Journal of cellular and molecular medicine. 2010; 14: 1338-48. doi:10.1111/j.1365-2281.2010.01896.x. Miura P, Aimrouche A, Clow C, Belanger G, Jasmin BJ. Brain-derived neurotrophic factor expression is repressed during myogenic differentiation
79. Miyauchi M, Tsuchiya K, Yoshida H, Yagyu S, Kikuchi K, Misawa A, et al. A complex contributes to the differentiation block in rhabdomyosarcoma. Cancer research. 2005; 65: 7056-70. doi:10.1158/0008-5472.can-05-1783.

80. Kondo H, Toyama T, Sugiuira S, Fujii Y, Yamashita H. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer research. 2008; 68: 5004-8. doi:10.1158/0008-5472.can-08-0180.

81. Yoshimoto N, Toyama T, Takahashi S, Sugiuira H, Endo Y, Iwasa M, et al. Distinct microRNA expressions in mice that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res Treat. 2011; 130: 331-9. doi:10.1007/s10549-011-1672-2.

82. Di Leva G, Gasparini P, Piovano C, Ngankeu A, Carofalo M, Taccioli C, et al. MicroRNA cluster 212-222 and estrogen receptor alpha interactions in breast cancer. J Clin Oncol. 2010; 28: 3926-36. doi:10.1200/jco.2009.241.

83. Adams BD, Cowee DM, White BA. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Molecular endocrinology (Baltimore, Md). 2009; 23: 1215-20. doi:10.1016/j.men.2009.06-002.

84. Munagala R, Aqil F, Vadhvanam MV, Gupta RC. MicroRNA `signature' during estrogen-mediated mammary carcinogenesis and its reversal by egf-like acid and retinoic acid signaling. Molecular cancer research. 2009; 7: 1503-13. doi:10.1158/mcr.2009.0216.

85. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008; 451: 147-52. doi:10.1038/nature06487.

86. Li L, Feng Z, Yu Z. Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival. J Med Genet. 2013; 49: 596-602. doi:10.1136/jmg-2013-100385.

87. Bensen JT, Tse CK, Nyantai SJ, Barnholdt-Sloan JS, Cole SR, Millikan RC. Association of germline microRNA SNP Y199 in prostate cancer: framing the risk of breast cancer and survival: the Carolina Breast Cancer Study. Cancer Causes Control. 2012; 23: 1099-1109. doi:10.1007/s10552-012-0187-z.

88. Gao R, Wu Q, Liu F, Yang W. Description of the CD313+ subpopulation of the breast cancer cell line MDA-MB-231. Cancers (Basel). 2012; 3: 141-6. doi:10.3390/cancers3010141.

89. Zhou L, Chen J, Li Z, Li X, Hu X, Huang Y, et al. Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS one. 2010; 5: e15224. doi:10.1371/journal.pone.0015224.

90. Torres-Martín M, Lassalette L, de Campos JM, Isla A, Gavilán J, Pinto CR, et al. Global Profiling in Vestibular Schwannomas Shows Critical Deregulation of MicroRNAs and Upregulation in Those Included in Chromosomal Region 14q32. PloS one. 2013; 8: e65868. doi:10.1371/journal.pone.0065868.

91. Vickers MM, Bar J, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JE, et al. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis. 2012; 29: 563-72. doi:10.1007/s10587-011-9615-7.

92. Yang Q, Zhang C, Huang B, Li H, Zhang R, Huang Y, et al. Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer. Eur J Gastroenterol Hepatol. 2013; 25: 953-7. doi:10.1097/MEG.0b013e3283596e91.

93. Wang C, Su Z, Sanai N, Xue X, Lu L, Chen Y, et al. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment. Oncology reports. 2012; 27: 1312-20. doi:10.3892/or.2012.1690.

94. Zhang T, Liu M, Wang C, Lin C, Sun Y, Jin D. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 2011; 31: 3859-63.

95. Stahlhut C, Suarez Y, Lu J, Mishima Y, Giraldes AJ. miR-1 and miR-206 regulate angiogenesis by modulating Vegfa expression in zebrafish. Development. 2012; 139: 4356-64. doi:10.1242/dev.083774.

96. Chen X, Yan Q, Li S, Zhou L, Yang H, Yang Y, et al. Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERalpha-positive endometrioid adenocarcinoma. Cancer Lett. 2012; 314: 41-53. doi:10.1016/j.canlet.2011.09.014.

97. Lin CC, Liu LZ, Addison JB, Wonderlin WF, Ivanov AV, Ruppert JM. A KLF4-miR-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. Molecular and cellular biology. 2011; 31: 2513-27. doi:10.1128/mcb.01899-10.

98. Parasarman MA, Dashwood WM, Wang R, Sreed HH, Williams DE, Ho E, et al. The role for low-miRNA levels in colon cancer: the miR-206/Kruppel-like factor 4 (KLF4) axis. Clin Epigenetics. 2012; 4: 1-16. doi:10.1186/1676-5902-4-16.

99. Wu J, Yang T, Li X, Yang Q, Liu R, Huang J, et al. Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Toxicol Appl Pharmacol. 2013; 267: 238-46. doi:10.1016/j.taap.2013.01.002.
105. Namlos HM, Meza-Zepeda LA, Baroy T, Ostenh IE, Kresse SH, Kuijser ML, et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PloS one. 2012; 7: e48066. doi:10.1371/journal.pone.0048066.

106. Luo Z, Zhang L, Li Z, Li X, Li G, Yu H, et al. In silico analysis of dynamic changes in microRNA expression profiles in stepwise progression of nasopharyngeal carcinoma. BMC medical genomics. 2012; 5: 3. doi:10.1186/1755-8794-5-3.

107. Liang LK, Toyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH, et al. MicroRNA expression profiles in the progression of prostate cancer from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol. 2011. doi:10.1016/j.jurooncol.2011.07.002.

108. Hidaka H, Seki N, Yoshino H, Yamashita T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012; 3: 44-57.

109. Wang R, Hu Y, Song G, Hao CJ, Cui Y, Xia HF, et al. MiR-206 regulates neural cells proliferation and apoptosis via Otx2. Cell Physiol Biochem. 2012; 29: 381-90. doi:10.1159/000338493.

110. Roccaro AM, Sacco A, Jia X, Azab AK, Maio P, Ngo HT, et al. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinaemia. Blood. 2010; 116: 1506-14. doi:10.1182/blood-2010-01-265686.

111. Shan ZX, Lin QX, Deng CY, Zhou JN, Lin P, Liu JL, et al. miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FERS Letters. 2010; 584: 3592-600. doi:10.1016/j.ferslet.2010.07.027.

112. Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, Zhu JN, et al. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochemical and biophysical research communications. 2009; 381: 597-601. doi:10.1016/j.bbrc.2009.02.097.

113. Westendorp B, Major JL, Nader M, Salih M, Leenen FH, Tuana BS. The E2F6 repressor activates gene expression in myocardium resulting in dilated cardiomyopathy. FASEB Journal : official publication of the Federation of American Societies for Experimental Biology. 2012; 26: 2569-79. doi:10.1096/fj.11-201374.

114. Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. The Journal of biological chemistry. 2009; 284: 31921-7. doi:10.1074/jbc.M109.046862.

115. Jalali S, Ramanathan GK, Parthasarathy PT, Aljubran S, Galam L, Yunus A, et al. MiR-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PloS one. 2012; 7: e46008. doi:10.1371/journal.pone.0046008.

116. Farber HW, Loscalzo J. Pulmonary arterial hypertension. The New England journal of medicine. 2004; 351: 1655-65. doi:10.1056/NEJMra035488.

117. Lewis A, Riddoch-Contragora J, Natanek SA, Donaldson A, Man WD, Moxham J, et al. Downregulation of the serum response factor/miR-71/miR-201 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. The Journal of biological chemistry. 2012; 384: 21769-79. doi:10.1074/jbc.M112.347306.

118. Guo XK, Zhang Q, Gao L, Li N, Chen XX, Feng WH. Increasing expression of microRNA 181 inhibits porcine reproductive and respiratory syndrome virus replication and has implications for controlling virus infection. J Virol. 2013; 87: 1159-71. doi:10.1128/jvi.02836-12.

119. Skovgaard K, Cigera S, Vaseby D, Podolska A, Breum SO, Durrwald R, et al. Expression of innate immune genes, proteins and microRNAs in lung tissue of pigs infected experimentally with influenza virus (H1N2). Innate Immun. 2010; 25: 1429-37. doi:10.1165/rr-2011-200309.

120. Olsen L, Klausen M, Helboe L, Nielsen FC, Werge T. MicroRNAs show suppressive microRNA Modulation in Pulmonary Arterial Hypertension. Curr Vasc Pharmacol. 2013.

121. Loewig L, Link H, Sorensen D, Wergeland BE, Jorgensen M, Eide T, et al. E2F6 activation modulates cell proliferation and apoptosis via Otx2. Cell Physiol Biochem. 2012; 29: 381-90. doi:10.1159/000338493.

122. Guo XK, Zhang Q, Gao L, Li N, Chen XX, Feng WH. Increasing expression of microRNA 181 inhibits porcine reproductive and respiratory syndrome virus replication and has implications for controlling virus infection. J Virol. 2013; 87: 1159-71. doi:10.1128/jvi.02836-12.

123. Skovgaard K, Cigera S, Vaseby D, Podolska A, Breum SO, Durrwald R, et al. Expression of innate immune genes, proteins and microRNAs in lung tissue of pigs infected experimentally with influenza virus (H1N2). Innate Immun. 2013. doi:10.1016/j.inu.2013.07.027.

124. Ge Y, Zhao K, Qi Y, Min X, Shi Z, Qi X, et al. Serum microRNA expression profile as a biomarker for the diagnosis of pertussis. Mol Biol Rep. 2013; 40: 1325-32. doi:10.1007/s11033-012-2176-9.

125. Olsen L, Klausen M, Helboe L, Nielsen FC, Werge T. MicroRNAs show mutually exclusive expression patterns in the brain of adult male rats. PloS one. 2009; 4: e7225. doi:10.1371/journal.pone.0007225.

126. Lehokzy A, Lau P, Tokesi N, Muja N, Hudson LD, Ovadi J. Tubulin polymerization-promoting protein (TIPPP/p25) is critical for oligodendrocyte differentiation. Cilia. 2010; 38: 157-68. doi:10.1002/glia.20099.

127. Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke, a journal of cerebral circulation. 2008; 39: 959-66. doi:10.1161/strokeaha.107.500736.

128. Lee ST, Chu K, Jung KJ, Kim JH, Hu HJ, Yoon H, et al. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neuroi. 2012; 72: 269-77. doi:10.1002/ana.23588.

129. Kusuda R, Cadetti F, Ravaneli MI, Sousa TA, Zanon S, De Luca FL, et al. Differential expression of microRNAs in mouse pain models. Molecular pain. 2011; 7: 17. doi:10.1186/1744-8069-7-17.

130. Zhou W, Li Y, Wang X, Wu L, Wang Y. MiR-206-mediated dynamic mechanism of the mammalian circadian clock. BMC Syst Biol. 2011; 5: 141. doi:10.1186/1755-0509-5-141.

131. Walden TB, Timmons JA, Keller P, Nedergaard J, Cannon B. Distinct expression of muscle-specific microRNAs (myomirs) in brown adipocytes. Journal of cellular physiology. 2009; 218: 444-9. doi:10.1002/jcp.21621.

132. Zheng D, Huang G, Zhang Y, Zeng Y, Xu Z, Zhao Y, et al. MicroRNA-1 and microRNA-206 suppress LXRalpha-induced lipogenesis in hepatocytes. Cell Metabol. 2013; 25: 1429-37. doi:10.1016/j.cmet.2013.03.003.

133. Soriano A, Jubierre L, Almazan-Moga A, Molist C, Roma J, de Toledo JS, et al. microRNAs as pharmacological targets in cancer. Pharmacological research : the official journal of the Italian Pharmacological Society. 2013; 75: 3-14. doi:10.1016/j.phrs.2013.03.006.

134. Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension. Curr Vasc Pharmacol. 2013.